Page 141 | Certara

Blog

Getting started with in-house development: storyboarding

Introducing our three-part blog series on getting started with in-house development. In this series, we’re…

CertaraFebruary 21, 2020

On-Demand Webinar

The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?

This webinar will explain how pricing has evolved for the rare disease drug market and…

CertaraFebruary 19, 2020

Blog

Getting started with in-house development: how does it work?

Introducing our three-part blog series on getting started with in-house development. In this series, we’re…

CertaraFebruary 10, 2020

On-Demand Webinar

How to Demonstrate Virtual Bioequivalence for Complex Dermal Generic Drugs

This webinar will explain how Certara expanded its PBPK Simcyp Simulator to incorporate an extensive…

CertaraJanuary 24, 2020

Poster

Visualization of Complex Trial Data in Non-Linear Mixed-Effect Analyses With Covariates

CertaraJanuary 17, 2020

Publication

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

CertaraJanuary 17, 2020

Publication

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

CertaraJanuary 17, 2020

On-Demand Webinar

AAPS Webinar – Pediatric Drug Development: Why It’s Critical to Submission Strategy and How Modeling, Regulatory, and Clinical Insights Shape Success

Learn how model-informed drug development, clinical pharmacology, and regulatory strategy support successful pediatric drug development…

CertaraJanuary 12, 2020

Blog

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…

CertaraDecember 19, 2019

Blog

Patient Engagement and Patient Centricity Series Part II: Types of Patient Advocates

Nirpal Virdee, Synchrogenix’s Global Head of Transparency and Disclosure recently sat down with Trishna Bharadia,…

CertaraNovember 11, 2019

Getting started with in-house development: storyboarding

The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?

Getting started with in-house development: how does it work?

How to Demonstrate Virtual Bioequivalence for Complex Dermal Generic Drugs

Visualization of Complex Trial Data in Non-Linear Mixed-Effect Analyses With Covariates

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

AAPS Webinar – Pediatric Drug Development: Why It’s Critical to Submission Strategy and How Modeling, Regulatory, and Clinical Insights Shape Success

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

Patient Engagement and Patient Centricity Series Part II: Types of Patient Advocates

Newsletter sign up

Quick links

Solutions

Contact